The synergistic anti-MM activity of CB-5083 and PIs can likely be explained by the VCP/p97-mediated retrotranslocation of the transcription factor NRF1, which affects the expression of proteasome subunit genes in the case of proteasome activity insufficiency. The gene discussed is VCP; the disease is Miyoshi myopathy.